Molecular Characterization of the Resistance of Mycobacterium tuberculosis to Second Line Drugs in Côte d’Ivoire
Purpose: To characterize the resistance of Mycobacterium tuberculosis to second line drugs using a line probe assay.
Methods: Multi-drug resistant strains of Mycobacterium tuberculosis isolated between December 2008 and December 2009 were tested for resistance to fluoroquinolones and second-line injectable drugs using GenoType® MTBDRsl.
Results: Thirty eight strains gave interpretable results. None of them had a mutation in the gyrA gene. Regarding second-line injectable drugs, 4 strains (11 %) were resistant to aminoglycosides/ capreomycin and all of them harbored A1401G mutation.
Conclusion: No extensive drug resistant strains were observed. A relatively high proportion of strains were resistant to at least one second-line injectable drug. Resistance mechanism seemed similar for all of them.
Keywords: Mycobacterium tuberculosis, Line probe assay, GenoType® MTBDRsl, Aminoglycosides Capreomycin, Mutation
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.